Skills · Bills & money · Verified

Prescription price check

Compare what a prescription costs with insurance, at cash price, and with discount cards at nearby pharmacies — without changing what the doctor prescribed.

Ask for it like this

  • “How can I pay less for my prescription?”
  • “Is a discount card cheaper than my insurance copay?”
  • “Compare pharmacy prices for a medication”

What’s true right now

Researched with AI and checked claim by claim against the full text of the cited pages by a second model; claims it couldn’t find were removed. Your assistant gets the same facts when it uses this skill. Confirm anything decisive on the official source.

the United States · updated 2026-10-09Medicare's 2027 Part D out-of-pocket cap rises to $2,400. Negotiated prices for 15 more drugs, including Ozempic and Wegovy, start Jan 1, 2027. Open enrollment runs Oct 15–Dec 7.
  • For 2027, the Medicare Part D yearly cap on out-of-pocket costs for covered drugs rises to $2,400, up from $2,100 in 2026. The maximum standard deductible rises to $700, up from $615. Monthly plan premiums and drugs a plan does not cover do not count toward the cap. (as of 2026-10-01) [1][3][4][5]
  • The temporary federal Part D Premium Stabilization Demonstration ends after 2026. The 2027 Part D base beneficiary premium is $41.33, up from $38.99, and Medicare open enrollment runs Oct 15 to Dec 7, 2026. (as of 2026-10-02) [4][6][2]
  • Negotiated Medicare prices for 15 more Part D drugs take effect Jan 1, 2027. Examples for a 30-day supply: $274 for Ozempic/Rybelsus/Wegovy, $175 for Trelegy Ellipta, $67 for Breo Ellipta, $136 for Linzess and $80 for Janumet. CMS estimates enrollees will save $685 million in out-of-pocket costs. (as of 2025-11-25) [8][7][9]
  • A KFF analysis of 32 brand-name drugs on TrumpRx found 17 priced below the average in peer countries and 15 priced above it. For example, Ozempic pen is $349 on TrumpRx versus a $126 average elsewhere. One outlet also noted that an insured patient's copay can be lower than the TrumpRx cash price. (as of 2026-09-25) [10][12][11]
  1. Medicare Part D 2027 Explained (quickrxspecialty.pharmacy)
  2. What's new for Medicare Part D in 2027? (humana.com)
  3. 2027 Medicare Part D Plans: Costs, Deductible & Cap (unitedmedicareadvisors.com)
  4. Medicare Part D Premium 2027: New Rates Announced, How Much Will You Pay? (govtschemes.org)
  5. Medicare Part D in 2027: Plans by State & City (mymedicareplans.org)
  6. Why Is 2027 Medicare Part D Costing More? $700 Deductible (gentlemedicareguide.com)
  7. Key Facts About Medicare Drug Price Negotiation (kff.org)
  8. CMS Unveils 2027 Medicare Drug Price Negotiation MFPs, Source Says 340B Price Still Lower for Some - 340B Report (340breport.com)
  9. CMS Announces Negotiated Drug Prices Effective in 2027 (laborfirst.com)
  10. TrumpRx claims the world's lowest drug prices. A new report raises doubts (usatoday.com)
  11. TrumpRx Drug Prices: Every Presidential Deals Medication (govfacts.org)
  12. TrumpRx claims the world's lowest drug prices. A new report raises doubts (yahoo.com)
the United Kingdom · updated 2026-10-09England's NHS prescription charge is frozen at £9.90 per item for 2026/27 and prescriptions stay free in Scotland, Wales and NI. Private prices for drugs such as Wegovy vary widely.
  • The NHS prescription charge in England is £9.90 per item for 2026/27. This is the second year in a row it has been frozen. Prescriptions are free in Scotland, Wales and Northern Ireland. (as of 2026-04-29) [7][8][9]
  • Prescription prepayment certificate (PPC) prices in England are also frozen for 2026/27: £32.05 for 3 months, £114.50 for 12 months and £19.80 for the HRT PPC. The 12-month PPC can be paid in 10 monthly Direct Debit instalments of £11.45. (as of 2026-04-29) [7][6][5]
  • From April 2026, NICE raised its cost-effectiveness thresholds for new medicines from £20,000–£30,000 to £25,000–£35,000 per QALY (quality-adjusted life year). Under the deal, the UK also committed to raising the net price the NHS pays for future new medicines by 25% from April 2026. (as of 2026-05-11) [10][11][12]
  • A Medicines UK report published on 28 September 2026 says 74 major biologic medicines, including semaglutide, will lose exclusivity between 2026 and 2032. It warns of a 'biosimilar void': up to 50 cheaper biosimilar copies may never launch in the UK. (as of 2026-09-29) [2][1][3]
  • Samsung Bioepis's aflibercept biosimilar SB15, a copy of Eylea that the MHRA approved in April 2025, was cleared by a settlement to launch in the UK from January 2026. Actual use depends on local NHS contracting. (as of 2026-09-29) [4]
  1. Medicines UK: UK Faces ‘Biosimilar Void’ After Patent Expiry - Pharmacy Business (pharmacy.biz)
  2. Supporting biosimilar development could unlock "massive demand", says trade body - The Pharmaceutical Journal (pharmaceutical-journal.com)
  3. UK Set to Miss Out on Off-Patent Drug Savings, Lobby Group Warns - Bloomberg (bloomberg.com)
  4. Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar (ophthalmologytimes.com)
  5. NHS Prescription Charge 2026: £9.90 Frozen, PPC & Exemptions — Walton Surgery (waltonsurgery.co.uk)
  6. NHS Prescription Prepayment Certificate (PPC) (pillcare.co.uk)
  7. NHS prescription charges remain at £9.90 - Community Pharmacy England (cpe.org.uk)
  8. NHS prescription charges frozen for the second year running - Community Pharmacy England (cpe.org.uk)
  9. How much is an NHS prescription in England? · Money Guide (moneyguide.org.uk)
  10. Arrangement between the United States of America and the United Kingdom on pharmaceutical pricing (HTML) - GOV.UK (gov.uk)
  11. Pharma Pricing & Reimbursement Laws 2026 (globallegalinsights.com)
  12. U.S.–UK Pharmaceutical Pricing Agreement: Learnings from the Published Text (insideeulifesciences.com)
the European Union · updated 2026-10-09Germany's prescription co-payments rise 50% to €7.50–€15 per pack from 1 Jan 2027. The EU Council adopted the pharma package on 28 Sep 2026, but it is not yet in force.
  • Germany: from 1 January 2027, the statutory health insurance (GKV) co-payment on prescription medicines stays at 10% of the pharmacy price but rises to a minimum of €7.50 and a maximum of €15 per pack, up from €5–€10. The co-payment can never be higher than the actual price of the medicine. (as of 2026-10-05) [3][4][5][7]
  • Germany: the annual cap on co-payments stays at 2% of gross annual income, or 1% for people with a recognised serious chronic illness. Insurers do not flag automatically when the cap is reached; exemption or refund applications must be filed. Extra costs above reference prices (Festbeträge) do not count toward the cap. (as of 2026-10-07) [7][8][4]
  • Germany: the GKV-BStabG ends the legal entitlement to homeopathic and anthroposophic medicines. Insurers may keep paying for them as optional extras only until the end of 2026. It also limits medical cannabis coverage to extracts, ending coverage of dried flowers. (as of 2026-07-30) [5][2][6]
  • Germany: the GKV-BStabG introduces tender-like rebate contracts for patented medicines, currently limited to five drug classes: JAK inhibitors, CGRP antagonists, PARP inhibitors, PCSK-9 inhibitors and PD-1/PD-L1 inhibitors. (as of 2026-07-29) [2]
  • EU: in May and June 2026, the EMA's CHMP committee recommended 3 new biosimilars and 3 new generic medicines for EU-wide authorisation. (as of 2026-07-08) [1]
  1. European Medicines Agency approvals of new medicines in May and June 2026 - ScienceDirect (sciencedirect.com)
  2. What does the GKV-BStabG Reform Change for Pharma Pricing & Reimbursement in Germany? And the Reforms Are Not Over: What to Expect From the New German Minister of Health and the Pharma Dialogue? (insideeulifesciences.com)
  3. Zuzahlung steigt ab 2027 (apotheke-adhoc.de)
  4. Krankenkassen-Spargesetz ab 2027: Zuzahlung, Familie, weiteres (buerger-geld.org)
  5. GKV-BStabG veröffentlicht: Erste Änderungen gelten bereits ab heute - DeutschesArztPortal (deutschesarztportal.de)
  6. GKV-Reform 2027: Was sich ändert (holsteiner-finanzkonzepte.de)
  7. Gesundheitsreform 2026/2027 - Die Techniker (tk.de)
  8. GKV-Reform: Chronisch Kranke zahlen ab 2027 mehr für Medikamente und Therapien (ad-hoc-news.de)
Canada · updated 2026-10-09Generic semaglutide is now sold in Canada, with cash prices from about $88. Sandoz got approval on Sept 18. Pharmacare still covers only BC, MB, PEI and Yukon.
  • Health Canada approved Sandoz Semaglutide, a generic version of Ozempic for adults with type 2 diabetes, in 0.25/0.5 mg and 1 mg pen presentations. The launch is still being prepared, and Sandoz expects no material revenue from it in 2026. (as of 2026-09-18) [1][2][4]
  • Generic semaglutide approvals in Canada so far: Dr. Reddy's Semaglutide Injection (approved April 28, 2026), Apotex's Apo-Semaglutide Injection (approved May 1, 2026; on the market since May 14, 2026), Apotex's Sevmia (approved June 29, 2026; the first generic for chronic weight management, referencing Wegovy), and Aspen products (approved July 17 and August 25, 2026). Approval does not confirm that a pharmacy has stock. (as of 2026-09-16) [3][5]
  • The pan-Canadian Pharmaceutical Alliance (pCPA), which negotiates drug prices for public plans, renewed its generic pricing agreement with the Canadian Generic Pharmaceutical Association (CGPA). The renewal took effect October 1, 2026, runs for 2 years, and keeps the tiered pricing framework and select-molecule pricing. Under the tiered framework, a new single-source generic is listed at 75% of the brand reference price and drops to 55% after about three months. The initiative applies to public plans, private plans and people paying out of pocket. (as of 2026-10-01) [6][7]
  • In British Columbia, the base PharmaCare dispensing fee rose from $10 to $11 on January 2, 2026. PharmaCare now pays one dispensing fee per patient per drug per day, up to two a day. (as of 2026-09-30) [8]
  1. Sandoz Canada receives Health Canada regulatory approval for (Pr)Sandoz® Semaglutide, a generic version of (Pr)Ozempic® - BioSpace (biospace.com)
  2. Sandoz receives regulatory approval for generic semaglutide in Canada, paving way to expand patient access to key GLP — 1 medicine (squawknews.com)
  3. Sandoz’s Generic Ozempic® (Semaglutide) Approved in Canada (pearceip.law)
  4. Sandoz Canada receives Health Canada regulatory approval for (Pr)Sandoz® Semaglutide, a generic version of (Pr)Ozempic® (ca.finance.yahoo.com)
  5. Sevmia (Generic Wegovy) Price in Canada (2026) (glp1prices.ca)
  6. Extended agreement for generic drug pricing (pcpa-app.ca)
  7. Canadian pharma companies extend generic drug pricing agreement to 2028 (benefitsandpensionsmonitor.com)
  8. The Business of Safe Supply - BC Politics Watch (bcpoliticswatch.substack.com)
Australia · updated 2026-10-09Most PBS prescriptions cost up to A$25 (A$7.70 concession) in 2026. On 1 Oct, Celltrion's tocilizumab biosimilar was listed, triggering a 25% cut to Actemra's price.
  • Since 1 January 2026, general patients pay up to A$25.00 per PBS prescription, down from A$31.60. Concession card holders pay up to A$7.70. The general amount will be indexed each year from 1 January 2027. (as of 2026-07-01) [1][2]
  • The 2026 PBS Safety Net thresholds are A$1,748.20 for general patients and A$277.20 for concession patients, counted per family per calendar year. Once a family reaches the threshold, general patients pay A$7.70 per script and concession patients pay nothing, apart from any premiums. Brand premiums, therapeutic group premiums and special patient contributions do not count towards the thresholds. (as of 2026-07-01) [3][1]
  • For PBS medicines priced below the co-payment, a pharmacy can charge the dispensed price plus up to A$1.48 for recording Safety Net spending and an optional fee of up to A$2.79. The total cannot exceed the A$25.00 co-payment, but delivery, after-hours fees and brand premiums can be added on top. (as of 2026-07-01) [1]
  • From 1 January 2026, the allowable discount on the general co-payment is nil, and concession patients can receive a discount of up to A$0.60. Pharmacists may choose to discount eligible general scripts with a Commonwealth price between A$25.00 and A$51.10. [2]
  • From 1 January 2026, general patients pay A$20.00 for outpatient medicines at public hospitals in every state and territory except Queensland. Hospitals under Pharmaceutical Reform Agreements charge up to A$25.00, and concession patients pay A$7.70. [2]
  • On 1 October 2026, Celltrion's Avtozma (tocilizumab) became the first tocilizumab biosimilar on the PBS, triggering a mandatory 25% statutory price cut for the originator Actemra. The same day, Yuflyma (adalimumab) 20 mg syringes and Omlyclo (omalizumab, hospital use) pens were also listed. (as of 2026-10-01) [4][8]
  • Amgen's Wezlana, an ustekinumab biosimilar to Stelara, was added to the PBS on 1 July 2026. Novo Nordisk's Tresiba Penfill (insulin degludec) for type 1 diabetes was listed the same day. (as of 2026-07-01) [6]
  • Outcomes of the July 2026 PBAC meeting, published 21 August 2026, recommended PBS listing for Biocon/Generic Health's Yesintek (ustekinumab). The TGA approved Actor's aflibercept biosimilars Aflivu and Ahzantive on 29 September 2026. Sandoz's Afqlir is still the only aflibercept biosimilar on the PBS. (as of 2026-09-29) [5][7]
  • As of 1 October 2026, no medicine is PBS-subsidised for weight management. Wegovy was recommended for a restricted listing (adults with established cardiovascular disease and obesity) in November 2025, but price negotiations were still unresolved. The PBS medicine status page says the tirzepatide (Mounjaro) listing process has ceased because the manufacturer is not proceeding. (as of 2026-10-01) [10][11][9]
  1. Fees, Patient Contributions and Safety Net Thresholds (pbs.gov.au)
  2. What are the current patient fees and charges? (pbs.gov.au)
  3. 5. The Safety Net Scheme (pbs.gov.au)
  4. Celltrion’s Biosimilar Tocilizumab First to be PBS Listed in Australia (pearceip.law)
  5. PBAC Recommends Reimbursement for Ustekinumab & Aflibercept Biosimilars (pearceip.law)
  6. New PBS Listings for Biosimilar Ustekinumab, Insulin Degludec, Rozanolixizumab & Tezepelumab Take Effect (pearceip.law)
  7. Actor’s Biosimilar Aflibercept Approved in Australia (pearceip.law)
  8. Pearce IP BioBlast® for the week ending 2 October 2026 (pearceip.law)
  9. Medicine Status (pbs.gov.au)
  10. Weight Loss Medication in Australia: What Is Approved (2026) (preptide.com.au)
  11. Is Wegovy on the PBS in Australia? 2026 Status (holisticchem.com.au)

What your assistant does

  1. Get the exact drug name, strength, form, quantity, and ZIP code, and whether the user has insurance. Do not ask about diagnoses or medical history — price comparison does not need them.
  2. Search cash prices and discount-card prices (GoodRx, SingleCare, and similar) at pharmacies near that ZIP code, plus mail-order options and Mark Cuban Cost Plus Drugs where the drug is listed.
  3. Search whether a generic or biosimilar exists, and whether the manufacturer runs a savings card or patient-assistance program.
  4. Show a short table: pharmacy, price, and how to pay (insurance copay, discount card, or cash). Note that discount-card purchases usually do not count toward an insurance deductible.
  5. If a cheaper generic or another form of the drug exists, tell the user to ask their doctor or pharmacist about it. Never suggest changing the drug, dose, or schedule yourself.